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In 1898, two dermatologists, William Anderson in England
and Johannes Fabry in Germany, separately described a
disease characterized by skin lesions, known as angiokera-
tomas. This issue contains two reports of Fabry disease
(FD) patients presenting with proteinuric chronic kidney
disease (CKD) but lacking angiokeratomas [1, 2]. These
cases illustrate the phenotypic heterogeneity of the
disease in females [1] and FD variants [2], the role of
genetic diagnosis [1] and renal biopsy [2] and recent ad-
vances in pathophysiology [1]. FD is caused by deﬁcient
activity of alpha-galactosidase A (α-GalA) due to mutations
in the X-chromosome GLA gene, leading to accumulation
of neutral glycolipids and eventual tissue injury and organ
dysfunction [3]. In classical FD males, α-GalA activity is
absent or nearly absent and there is an early onset of acro-
paresthesias, angiokeratoma and hypohydrosis followed by
life-threatening cardiac, central nervous system and kidney
disease leading to end-stage renal disease (ESRD) at a
mean age of 40 years [3, 4].
FD in females
Although FD is an X-linked disorder, women should not
be considered as just carriers of the disease. The term
X-linked recessive, which used to be applied to this dis-
order, should probably be discontinued and FD should
simply be described as following an ‘X-linked inheritance’.
The same is true for another well-known X-linked renal
disorder: Alport’s syndrome. FD females may show a
milder form of the disease with signs and symptoms
starting later as reported by Lukas et al. in this issue of
CKJ [1]. Although this milder form is true for most cases,
some women with FD show a severe and aggressive pres-
entation indistinguishable from that seen in males [5].
The explanation for the wide variability in clinical presen-
tation may be partly due to lyonization [6], a process
where one copy of the X-chromosome is randomly inacti-
vated in all cells of the female embryo. Therefore,
females are essentially a ‘mosaic’ of normal and mutant
cells in varying proportions. In X-linked diseases, females
may show a severe phenotype as a consequence of
skewed X-chromosome inactivation, resulting in a higher
percentage of the wild-type X-chromosome being inacti-
vated in a speciﬁc tissue. A high percentage of women
with FD show vital organ damage as shown by Lukas
et al. [1]. Although most females present scarce renal
signs, some may show proteinuria as stated by Lukas
et al. [1, 7, 8] and even ESRD. In a retrospective study
of 279 affected males and 168 females with FD,
the mean rate of estimated glomerular ﬁltration rate
decline was −1.02 mL/min/1.73 m2 per year for females
compared with −2.93 mL/min/1.73 m2 per year for males
[9]. While this is the expected rate of renal function
decline in correlation with age in female patients, it is twice
the expected rate in males. ESRD was less prevalent
in females, who account for around 10% of FD patients
on renal replacement therapy [4]. However, those females
who reach ESRD do so at the same mean age as males
[4, 8].
Renal variant
Late-onset FD variants are generally caused by less
severe mutations, resulting in a residual enzymatic
activity of 1–15% of normal, and phenotypically may not
display many of the multisystem symptoms of classical
FD. Cardiac and renal variants have been recognized
based on predominant or exclusive symptoms related to
these organs [10, 11]. In this issue, Al-Salam et al. report
a case of renal variant FD [2]. Although the clinical varia-
bility of FD had been recognized previously, the term
‘renal variant’ was coined in 2003 [11]. Haemodialysis
patients in Japan were previously screened and ﬁve male
FD patients who had initiated haemodialysis at 25–56
years of age with a clinical diagnosis of chronic glomeru-
lonephritis were found, a diagnosis also entertained in
the case by Al-Salam et al. [2]. Angiokeratoma, corneal
opacities, acroparesthesias and hypohidrosis were not ob-
served, but most had left ventricular hypertrophy, a
common ﬁnding in CKD. In an additional patient with acro-
paresthesias, the FD diagnosis had been missed in a renal
biopsy where, in retrospect, deposits were observed [11].
Thus, the renal variant may display severe and early renal
disease, despite relatively high residual enzymatic activity
[11]. A correct understanding of the pathogenesis of FD is
required to fully understand this phenotypic variability.
Pathogenesis of kidney injury in FD
The enzymatic defect in FD causes intracellular accumu-
lation of neutral glycosphingolipids, mainly globotriaosyl-
ceramide [GL-3; GB-3, ceramide trihexoside (CTH)] and, as
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observed in the report by Lukas et al. [1], increased circu-
lating and even urinary levels of Gb3 and globotriaosyl-
sphingosine (Lyso-Gb3) [12]. These lipids have been
confused in the literature [13]. Lyso-Gb3 is a deacylated
metabolite of Gb3. The loss of a fatty acid makes lyso-Gb3
more soluble than Gb3. How the accumulation of these
glycolipids contributes to Fabry nephropathy is unclear
(Figure 1). It was initially suggested that glycolipid
accumulation in endothelial cells led to endothelial
dysfunction or physical obstruction of small vessels and
resultant ischaemic tissue injury. The lack of endothelial
deposits in a non-dialysis septuagenarian with a cardiac
variant and extensive podocyte deposits was interpreted
as supporting the key role of the endothelium in promot-
ing early ESRD. However, this patient had proteinuria and
Stage 3 CKD [14]. Younger patients with proteinuria and
Stage 3 CKD have been described that had podocyte but
not endothelial deposits [15]. Endothelial deposits may be
a surrogate marker for extensive glycolipid deposition
rather than a cause of ESRD. Indeed, severe cardiac ﬁbro-
sis was observed in lethal cardiac variants characterized
by cardiomyocyte deposits in the absence of endothelial
deposits [16]. In this regard, FD nephropathy is a progress-
ive proteinuric nephropathy of metabolic origin [8], fea-
tures shared by diabetic nephropathy. Podocyte injury is
considered central to proteinuric nephropathies. Podocyte
apoptosis, podocytopenia and increased synthesis of ex-
tracelullar matrix are early features of diabetic nephropa-
thy. Evidence is accumulating supporting a central role of
podocyte injury in FD. Thus, in FD children podocyte, but
not endothelial, inclusion volume density increases pro-
gressively with age, along with the foot process width,
which correlates with proteinuria [17]. Furthermore,
similar to the effects of high glucose, lyso-Gb3 elicits in
cultured human podocytes a pro-ﬁbrotic, proapoptotic
response characterized by increased TGFβ-1-mediated
extracellular matrix production and increased CD74 [18].
Increased CD74 is found in human podocytes in diabetic
nephropathy [19]. Both in FD males and in females, protei-
nuria is a key determinant of CKD progression, either in
natural history or in enzyme-treated populations [20, 21].
Proteinuria, contrary to other features of FD, hardly im-
proves with enzyme replacement therapy (ERT) [22, 23].
Since podocyte deposits are difﬁcult to clear by ERT,
Fig. 1. Current understanding of the pathogenesis of FD nephropathy. Like diabetic nephropathy, FD nephropathy is a progressive proteinuric
nephropathy of metabolic origin. Three non-mutually exclusive mechanisms may contribute to the progression of FD nephropathy. (i) The classical view
held that glycolipid deposits in endothelial cells led to endothelial dysfunction or physical obstruction of small vessels. This would lead to ischaemic
kidney injury. Of note, endothelial dysfunction is also a feature of both diabetes and CKD. (ii) A second mechanism would be glycolipid deposits inside
podocytes, which might lead to podocyte dysfunction and/or injury through yet uncharacterized molecular mechanisms. (iii) A third possibility is that
soluble metabolites, such as globotriaosylsphingosine (Lyso-Gb3), because of their presence either in the extracellular milieu or inside the cell, may
elicit stress responses in podocytes, leading to the expression of receptors for cytokines, such as the macrophage migration inhibition factor (MIF)
receptor CD74 or secretion of cytokines, such as TGFβ1, which, in turn, promotes the secretion of extracellular matrix. Local MIF overexpression in
podocytes is known to lead to proteinuria and ESRD in mice. This third mechanism would be shared with diabetic nephropathy, in which accumulated
metabolites, such as glucose, elicit the expression of CD74 and secretion of TGFβ1 by podocytes, contributing to excessive extracellular matrix
deposition and ﬁbrosis. Cardiac and renal ﬁbrosis are key features of FD. Interestingly, vitamin D receptor activation by either paricalcitol or calcitriol, an
action that protects podocytes from high glucose-induced stress [30], also protected podocytes from activation induced by lyso-Gb3 [19]. Activation of
podocytes by lyso-Gb3 is the only potential mechanism for FD nephropathy that has actually been demonstrated to exist in cultured renal cells [19].
Globotriaosylceramide [GL-3; Gb3, ceramide trihexoside (CTH)] contains three hexose residues and two fatty acids and is the main metabolite
accumulated inside FD cells. Globotriaosylsphingosine (Lyso-Gb3) is a deacylated metabolite of Gb3. The loss of a fatty acid makes lyso-Gb3 more
soluble than Gb3.
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contrary to endothelial deposits, this further supports a
key role of podocyte injury in FD [24]. The deﬁnite unravel-
ling of the mechanisms and role of podocyte injury in the
pathogenesis of Fabry nephropathy awaits the availability
of adequate FD animal models.
Diagnosis of FD
Diagnosis of FD is usually ﬁrst suspected on clinical basis.
However, in this issue, two reports show how difﬁcult it
can be to diagnose FD due to the phenotypic variability in
females [1] or unusual clinical features [2]. The latter case
also illustrates both the power of renal biopsy in suspected
cases of FD in the context of absent or overlooked classical
systemic symptoms or family history, and the limitations
of renal biopsy when electron microscopy or an expert
pathologist is not available. Even in typical cases, recogniz-
ing the early manifestations in clinical practice may be
challenging. When these signs or symptoms raise the
suspicion of FD, appropriate biochemical and/or genetic
conﬁrmation is needed. The demonstration of a deﬁcient
activity of α-galactosidase in plasma, leucocytes or whole
blood is the reference laboratory method, which should be
used to screen males for FD. A plasma assay may
occasionally lead to false diagnosis and should be con-
ﬁrmed by a leucocyte assay or genetic analysis [25].
However, as reported by Lukas et al. in this issue, the
α-galactosidase levels are normal in ∼50% of females [1].
Therefore, in females the deﬁnitive diagnostic conﬁrmation
should be made by genetic analysis. Direct sequencing is
easy because of the small size of the gene (7 exons) and
has become widely available. It should be carried out to
conﬁrm any suspected case of FD. A method that uses
ﬁlter paper cards containing dried blood spots has been
set up for both α-galactosidase levels determination
and genetic screening. All kinds of mutations have been
described in the α-galactosidase gene: missense or
nonsense point mutations, splicing mutations, small
deletions or insertions and large deletions. There is
neither a hot spot for mutations or a common mutation
in this gene. Most mutations are isolated and >600
mutations have been described to date [26]. The majority
of these mutations render a nonfunctional enzyme.
Two issues may complicate genetic studies. First, direct
sequencing of the gene may miss some cases as
reported by Lukas et al. [1]. The use of multiplex ligation-
dependent probe ampliﬁcation (MLPA) is recommended
in cases where a decreased enzyme activity is not associ-
ated with the identiﬁcation of a pathogenic mutation
[27]. The second issue is assessing the pathogenicity of
base pair changes. R118C was described in newborn
screening as a late-onset mutation based on cell culture
activity data, but, at the time, not a single patient with
FD symptoms carrying this mutation had been described
[28]. Renal variant FD was diagnosed by electron
microscopy in a renal biopsy in a male hemizygote for the
C174G mutation [15]. However, the single nucleotide poly-
morphism database of functional effects had considered
C174G a non-pathogenic polymorphism based on pre-
dicted functional effects assessed by screening for non-
acceptable polymorphisms and sorting intolerant from
tolerant scores [29]. MLPA should be considered in these
cases to search for additional genetic defects. Finally,
as indicated by Lukas et al., there is an active ﬁeld of
research on the role of assessment of different glycolipid
metabolites in body ﬂuids in the diagnosis and monitoring
of FD [1].
Summary
In summary, the articles presented in the current issue of
CKJ focus our attention towards ‘non-typical’ forms of
the disease. Patients with unusual clinical or genetic
features contribute to unravelling the pathogenesis of
FD nephropathy. Considering the different diagnosis
approaches we have nowadays and, above all, the avail-
ability of ERT, it is important to raise the suspicion of FD
when we face unexplained proteinuric CKD in either
males or females.
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